(Press-News.org) Lugano, Switzerland, 28th September -- Research institutes, regulators and the pharmaceutical industry are urged to cooperate to develop new approaches to testing cancer drugs, in order to bring the revolution in personalised medicine to patients across Europe, says the European Society for Medical Oncology.
It has become clear in recent years that each patient's cancer has individual characteristics that are potentially amenable to "personalised" treatments that target those characteristics. But there is still a great deal of work to be done to ensure patients benefit from these developments as quickly as possible.
"We are approaching a time when it will be possible to analyse the tumours of many patients to help us select the most appropriate treatment and to personalize treatment," said ESMO spokesperson Marina Garassino of the Division of Medical Oncology at the Italian National Institute of Cancer.
Selecting drugs for individual patients helps avoid useless treatments, minimise toxicity and reduce costs for society. In an ideal situation, oncologists would like to be able to use such methods to ensure every single patient is treated with the best possible drugs, Garassino said.
A major challenge facing researchers is that it is not always feasible to perform the kind of large clinical trials that regulators have demanded in the past to prove the value of new treatments.
"We are used to comparing different treatments using large phase III trials, where thousands of patients are randomized," Garassino explained.
"This is feasible when the disease is frequent but not when we are working with small groups of patients who have particular tumour characteristics. In those cases, we need to work closely with statisticians to develop new methodological approaches."
"Regulatory agencies must take into consideration that these kinds of studies can provide important, reliable information about these new drugs," Garassino said. "ESMO would like to encourage regulatory agencies and governments to implement better strategies in research and drug development. Secondly, we feel it is vital that more educational events are created for patients, to increase their awareness that in 2013 it is possible to personalize treatment for many tumors."
At the European Cancer Congress 2013 today, researchers presented data from an early stage phase II study that illustrated one such approach. In the trial, scientists compared targeted therapy based on molecular profiling against conventional therapy in patients with any type of refractory cancer1.
Patients in the trial have their tumours tested using three different methods, including the assessment of hot spot mutations, gene copy number alterations and expression of oestrogen, progesterone and androgen receptors. Their treatments will be based on these tests, and the primary endpoint will be progression-free survival.
So far, 143 patients have been included in the study, with early results showing that comprehensively profiling the tumour in this way was safe, feasible and compatible with clinical practice. The study authors also found that many tumours carried mutations that made their cancer susceptible to drugs that are already available, Garassino noted.
"This is an important study," Garassino said. "At a time when there are an increasing number of molecular profiling studies being performed, what makes this one particularly noteworthy is that they were able to identify candidate genes when there was already a drug for the selected target."
###
Notes to Editors
References
1. C. Le Tourneau, E. Mitry, A. Goncalves, N. Isambert, C. Gavoille, O. Tredan, J.P. Delord, M. Campone, X. Paoletti, M. Kamal. Randomised phase II trial comparing therapy based on tumour molecular profiling versus conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trial [European Cancer Congress, ECC2013, Saturday 28 September 2013, 14:30-16:30, Hall 4, Poster Session: Diagnostics/Biomarkers – Expression Profiling]
About the European Society for Medical Oncology
The European Society for Medical Oncology (ESMO) is the leading European professional organization committed to advancing the specialty of medical oncology and promoting a multidisciplinary approach to cancer treatment and care.
ESMO's mission is to advance cancer care and cure through fostering and disseminating good science that leads to better medicine and determines best practice.
ESMO's scientific journal, Annals of Oncology, ranks among the top clinical oncology journals worldwide. ESMO events are the meeting place in Europe for medical oncologists to update their knowledge, to network and to exchange ideas.
To find out more about ESMO, please visit: http://www.esmo.org
New approaches to testing cancer drugs needed -- ESMO press commentary
2013-09-30
ELSE PRESS RELEASES FROM THIS DATE:
A review concerning relationships and independence of human number, time and space processing
2013-09-30
Perception of NTS are basic cognitive processes for humans to interact with their environment. Whether a common magnitude system exits for NTS processing is such an important question to investigate. Following and guided by previous researchers, Dr. Yalin Chen and Chang Liu, from the Laboratory of Cognitive Neuroscience and the School of Psychology, Nanjing Normal University, China, reviewed present evidence and provided some comments concerning this question. Their work, entitled "Relationships and independence of human number, time, and space processing", was published ...
Climate change: Fast out of the gate, slow to the finish the gate
2013-09-30
Washington, D.C.— A great deal of research has focused on the amount of global warming resulting from increased greenhouse gas concentrations. But there has been relatively little study of the pace of the change following these increases. A new study by Carnegie's Ken Caldeira and Nathan Myhrvold of Intellectual Ventures concludes that about half of the warming occurs within the first 10 years after an instantaneous step increase in atmospheric CO2 concentration, but about one-quarter of the warming occurs more than a century after the step increase. Their work is published ...
Young children recognize cigarette brands in developing countries with most smokers
2013-09-30
Nearly two-thirds of young children in low- and middle-income countries can identify cigarette brand logos, according to a study from researchers at the University of Maryland School of Public Health (UMD SPH) and the Johns Hopkins Bloomberg School of Public Health (JHSPH).
The study, published in the journal Pediatrics, examined the reach of tobacco and cigarette marketing among some of the world's most vulnerable populations, sampling five and six year-old children from Brazil, China, India, Nigeria, Pakistan and Russia. These countries were selected because they have ...
Beyond the little blue pill: scientists develop compound that may treat priapism
2013-09-30
Bethesda, MD -- It's not the little blue pill famous for helping men get big results, but for those who need it, the outcome might be even more significant. A new research report published online in The FASEB Journal, offers hope to men who experience priapism. This condition, which is often seen in men with sickle cell disease, causes erections lasting so long that they cause permanent damage to the penis. Specifically, a compound, called "C6'" offered mice -- with and without sickle cell disease -- relief by normalizing nitric oxide levels in penile blood. In addition ...
Niacin, the fountain of youth
2013-09-30
Who would not want to live a long and healthy life? A freely available food supplement could help in this respect, scientists from ETH Zurich have demonstrated in roundworms. Vitamin B3 – also known as niacin – and its metabolite nicotinamide in the worms' diet caused them to live for about one tenth longer than usual.
As an international team of researchers headed by Michael Ristow, a professor of energy metabolism, has now experimentally demonstrated, niacin and nicotinamide take effect by promoting formation of so-called free radicals. "In roundworms, these reactive ...
Erratic proteins: New insights into a transport mechanism
2013-09-30
The outer membrane of bacteria contains many proteins that form tiny pores. They are important for absorbing nutrients and transmitting signals into the cell. The research group of Sebastian Hiller, Professor of Structural Biology at the Biozentrum, University of Basel, has now shown for the first time at atomic resolution, that these pore proteins are transported in an unstructured, constantly changing state to the outer bacterial membrane. This landmark study was recently published in the scientific journal "Nature Structural and Molecular Biology".
The cell membrane ...
Alcohol leaving the UK charts with a hangover
2013-09-30
London -- Are we allowing alcohol marketing to children and teens via the music they love? As many as one in five songs in the UK top ten today include references to alcohol -- a figure rising partly due to US-imported songs. What impact is this having on the youth of today? Experts warn that fresh evidence demonstrates that public health messages on alcohol may no longer be audible over the louder message from some sections of the music industry.
Researchers from Liverpool John Moores University, UK led by Katherine Hardcastle discuss their findings in: "Trends in alcohol ...
Trial combining anti-cancer drug and radiotherapy may lead to treatment for brain tumor
2013-09-30
Results from a clinical trial of a new treatment for glioblastoma suggest that researchers may have found a new approach to treating this most aggressive of brain tumours, as well as a potential new biological marker than can predict the tumour's response to treatment.
Presenting the research to the 2013 European Cancer Congress (ECC2013) [1] today (Monday), Professor Wolfgang Wick will say that combining radiotherapy with an anti-cancer drug called APG101 – a fusion protein similar to an antibody – blocks a cell-signalling pathway called CD95 that plays a crucial role ...
First estimate of radiotherapy dose wasted in compensating for between-treatment tumor growth
2013-09-30
For the first time, researchers have estimated the daily dose of radiotherapy that could be wasted in compensating for cancer cell growth that occurs overnight and during weekends in patients with early breast cancer.
In research to be presented to the 2013 European Cancer Congress (ECC2013) [1] today (Monday), Professor John Yarnold will say that, until now, there has been contradictory evidence as to whether gaps between radiotherapy treatments, for instance overnight or at weekends, makes any difference to the overall effectiveness of radiotherapy on breast cancer, ...
Do black holes have hair?
2013-09-30
A black hole. A simple and clear concept, at least according to the hypothesis by Roy Kerr, who in 1963 proposed a "clean" black hole model, which is the current theoretical paradigm. From theory to reality things may be quite different. According to a new research carried out by a group of scientists that includes Thomas Sotiriou, a physicist of the International School for Advanced Studies (SISSA) of Trieste, black holes may be much "dirtier" than what Kerr believed.
According to the traditional model, black holes are defined by only two quantities: mass and angular ...